Is immune escape via human leukocyte antigen expression clinically relevant in chronic lymphocytic leukemia? Focus on the controversies

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 473-477

  Guillaume, Nicolas ^a,b   Marolleau, Jean Pierre ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Chronic lymphocytic leukemia; HLA; Human leukocyte antigen; Prognostic factor; Tumor immunogenicity

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA DRB1 ANTIGEN; HLA G ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN KINASE ZAP 70; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; B CELL LEUKEMIA; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; TUMOR ESCAPE;

DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LOSS OF HETEROZYGOSITY; MUTATION; PROGNOSIS; RECEPTORS, NATURAL KILLER CELL; TUMOR ESCAPE;

EID: 84875380481     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.12.021     Document Type: Review

References (31)

1. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 2009, 411:380-384.
2. Rajalingam R. Overview of the killer cell immunoglobulin-like receptor system. Methods Mol Biol 2012, 882:391-414.
3. Lion E., Willemen Y., Berneman Z.N., Van Tendeloo V.F.I., Smits E.L.J. Leukemia 2012, 26:2019-2026.
4. Del Campo A.B., Carretero J., Aptsiauri N., et al. Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 2012, 79:147-154.
5. Cramer P., Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know?. Nat Rev Clin Oncol 2011, 8:38-47.
6. Demanet C., Mulder A., Deneys V., et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. Blood 2004, 103:3122-3130.
7. Verheyden S., Ferrone S., Mulder A., et al. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells. Cancer Immunol Immunother 2009, 58:855-865.
8. Ziegler H.W., Kay N.E., Zarling J.M. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981, 27:321-327.
9. Katrinakis G., Kyriakou D., Papadaki H., et al. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol 1996, 96:16-23.
10. Kay N.E., Zarling J.M. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984, 63:305-309.
11. Alvarez-Mon M., Casas J., Laguna R., et al. Clinical signification of natural killer activity in B-cell chronic lymphocytic leukemia. Eur J Haematol 1987, 38:268-273.
12. Costello R.T., Knoblauch B., Sanchez C., et al. Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology 2012, 135:151-157.
13. Drenou B., Tilanus M., Semana G., et al. Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas. Br J Haematol 2004, 127:40-49.
14. Jimenez P., Canton J., Collado A., et al. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 1999, 83:91-97.
15. Crowther-Swanepoel D., Di Bernardo M.C., Jamroziak K., et al. Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. Br J Haematol 2011, 154:229-233.
16. Shah N., Decker W.K., Lapushin R., et al. HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. Leukemia 2011, 25:1036-1039.
17. Karabon L., Jedynak A., Giebel S., et al. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens 2011, 78:129-138.
18. Das H., Groh V., Kuijl C., et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001, 15:83-93.
19. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3:781-790.
20. Nuckel H., Switala M., Sellmann L., et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010, 24:1152-1159.
21. Salih H.R., Rammensee H.G., Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002, 169:4098-4102.
22. Groh V., Wu J., Yee C., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
23. Rouas-Freiss N., Goncalves R.M., Menier C., et al. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997, 94:11520-11525.
24. Carosella E.D., HoWangYin K.H., Favier B., et al. HLA-G-dependent suppressor cells: diverse by nature, function, and significance. Hum Immunol 2008, 69:700-707.
25. Sebti Y., Le Friec G., Pangault C., et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003, 64:1093-1101.
26. Giannopoulos K., Schmitt M., Kowal M., et al. The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). Leuk Res 2008, 32:1815-1819.
27. Nückel H., Rebmann V., Dürig J., et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005, 105:1694-1698.
28. Erikci A.A., Karagoz B., Ozyurt M., et al. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker?. Hematology 2009, 14:101-105.
29. Rouas-Freiss N., Moreau P., Ferrone S., et al. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res 2005, 65:10139-10144.
30. Yan W.H. Human leukocyte antigen-G in cancer: are they clinically relevant?. Cancer Lett 2011, 311:123-130.
31. Perez-Chacon G., Rosado S., Rebolleda N., et al. Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. Int J Lab Hematol 2009, 31:327-337.